<DOC>
	<DOCNO>NCT00664378</DOCNO>
	<brief_summary>This clinical research study design test safety CYT997 give patient multiple myeloma test CYT997 activity cancer .</brief_summary>
	<brief_title>Efficacy Study CYT997 Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Diagnosis multiple myeloma per International Working Group ( IWG ) criterion Have receive least 1 4 prior line therapy Have fail respond recently administer antimyeloma therapy Have life expectancy least 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 3 At registration absolute neutrophil count &gt; 1x10^9/L platelet count &gt; 50 x 10^9/L unsupported At registration bilirubin le 1.5 x upper limit normal transaminase le 2 x upper limit normal serum creatinine le 0.19 mmol/L Written inform consent Must agree adequate contraceptive measure indicate Patients monoclonal gammopathy undetermined significance Known suspect hypersensitivity CYT997 Patient uncontrolled intercurrent illness Active infection illnesses precludes chemotherapy administration patient compliance . Pregnant lactating woman . Patients receive investigational agent last 3 week prior start treatment . Patients follow condition exclude : myocardial infarction stroke within 6 month unstable angina pectoris acute ischemic change ECG history diabetic retinopathy symptomatic peripheral arterial disease major surgery last 30 day Patients uncontrolled diarrhea despite optimal medication history acute gastrointestinal bleeding Patients baseline prolongation QTc interval Common Terminology Criteria ( CTC ) Grade 1 ( QTc &gt; 0.450.47 sec ) great Patients impaired cardiac function clinically significant cardiac disease , include one following : left ventricular ejection fraction ( LVEF ) &lt; 45 % determine multigated acquisition ( MUGA ) scan echocardiogram ; complete leave bundle branch block ; obligate use cardiac pacemaker ; congenital long QT syndrome ; history presence ventricular tachyarrhythmia ; presence unstable atrial fibrillation ( ventricular response &gt; 100 bpm ) . Patients stable atrial fibrillation eligible , provide meet cardiac exclusion criterion ; clinically significant rest bradycardia ( &lt; 50 bpm ) ; right bundle branch block + leave anterior hemiblock ( bifascicular block ) ; angina pectoris ≤ 3 month prior start study drug ; acute myocardial infarction ( MI ) ≤ 3 month prior start study drug ; clinically significant heart disease ( e.g. , congestive heart failure ( CHF ) , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) . Patients currently receive treatment medication know prolong QTc interval and/or induce Torsades de Pointes arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Multiple myeloma , relapse , refractory</keyword>
</DOC>